Business
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in the European Union (EU)
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in the European Union (EU).
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in the European Union (EU)\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in the European Union (EU)\nPR Newswire\nSAN DIEGO, March 5, 2020\n\n\n\nSAN DIEGO, March 5, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the European Patent Office has issued European Patent EP3094318B1 (the \"Patent\") specific to \"Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy\" to its portfolio investment company Kannalife, Inc. (\"Kannalife\") (OTCQB: KLFE). This is the sixth patent grant that Kannalife has received. \nKannalife will utilize the patent to further explore the application and potential of new molecular entities (NMEs) across epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson's disease, Alzheimer's, Huntington's disease, and amyotrophic lateral sclerosis (ALS).\n\"With this patent, Kannalife has now expanded its robust intellectual property portfolio to include six patents and broadened its reach into the European Union,\" said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. \"Kannalife's research has the potential to make a global impact as their growing portfolio of international patents pushes forward their go-to-market strategy.\"\nIn 2018, Europe was responsible for 23.2% of the world's pharmaceutical sales with the size of the market in the EU-5 (United Kingdom, Germany, Spain, France, and Italy) set to grow by 25% between 2017 and 2022.\n\"We are very pleased to have received a notice of grant from the EU regarding our ...